loading page

Behind XRCC1 Arg399Gln polymorphism: protection factor of laryngeal cancer
  • +3
  • Isabela Firigato,
  • Otavio Curioni,
  • Juliana Antonio,
  • Mariana Silva,
  • Gilka Gattás,
  • Fernanda Goncalves
Isabela Firigato
FMUSP
Author Profile
Otavio Curioni
Hospital Heliópolis
Author Profile
Juliana Antonio
FMUSP
Author Profile
Mariana Silva
FMUSP
Author Profile
Gilka Gattás
FMUSP
Author Profile
Fernanda Goncalves
FMUSP

Corresponding Author:[email protected]

Author Profile

Abstract

Laryngeal cancer is the second most common head and neck cancer worldwide, which has been considering a serious global health problem due to the high morbidity and mortality. Tumour risk factors include the DNA repair gene polymorphisms, but their contribution for metastasis and/or second primary tumour development has been seldom investigated. Objective (s): The present study evaluated the possible association between the DNA repair gene polymorphisms and laryngeal cancer risk, metastasis and/or second primary tumour in a hospital-based case-control study that comprised 149 laryngeal cancer patients and 448 controls from Heliópolis Hospital, São Paulo, Brazil. Design: The single nucleotide polymorphisms (SNPs) of the genes XRCC1 (Arg194Trp; Arg399Gln), XPD (Lys751Gln) and XRCC3 (Thr241Met) were analysed by TaqMan SNP Genotyping Assays. Results: The heterozygous genotype (OR 0.63, 95% CI 0.41-0.96) as well as the mutated homozygous genotype (OR 0.29, 95% CI 0.13-0.66) of XRCC1 (Arg399Gln) decreased the laryngeal cancer risk, even though none of the genes polymorphisms was associated with metastasis and/or second primary tumour development. Conclusion: The determination of the XRCC1 (399Gln) genotype might be applied as a molecular predictor of laryngeal cancer among individuals who are highly exposed to cigarette smoking carcinogens and improve the prognostic of the disease.